Invivyd (IVVD) Expected to Announce Quarterly Earnings on Thursday

Invivyd (NASDAQ:IVVD) is expected to issue its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $15.5150 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 5, 2026 at 8:30 AM ET.

Invivyd Trading Down 5.8%

NASDAQ:IVVD traded down $0.10 on Tuesday, hitting $1.62. 2,349,790 shares of the stock were exchanged, compared to its average volume of 2,795,892. The stock has a fifty day moving average of $2.07 and a 200-day moving average of $1.81. The stock has a market cap of $377.65 million, a PE ratio of -3.45 and a beta of 0.61. Invivyd has a fifty-two week low of $0.46 and a fifty-two week high of $3.07.

Insider Activity at Invivyd

In related news, insider Jill Andersen sold 34,939 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total transaction of $55,203.62. Following the transaction, the insider owned 181,736 shares of the company’s stock, valued at approximately $287,142.88. This trade represents a 16.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO William E. Duke sold 20,964 shares of Invivyd stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total transaction of $33,123.12. Following the completion of the sale, the chief financial officer owned 107,717 shares of the company’s stock, valued at $170,192.86. This trade represents a 16.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 227,172 shares of company stock worth $354,534. 25.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Invivyd

Institutional investors and hedge funds have recently modified their holdings of the business. Jain Global LLC bought a new position in shares of Invivyd during the 4th quarter worth about $122,000. Squarepoint Ops LLC grew its position in Invivyd by 188.9% during the third quarter. Squarepoint Ops LLC now owns 107,831 shares of the company’s stock worth $119,000 after buying an additional 70,508 shares in the last quarter. Bridgeway Capital Management LLC bought a new position in Invivyd during the third quarter valued at about $109,000. Mangrove Partners IM LLC acquired a new position in Invivyd in the 4th quarter valued at approximately $104,000. Finally, Jefferies Financial Group Inc. acquired a new position in Invivyd in the 3rd quarter valued at approximately $102,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Zacks Research raised shares of Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Invivyd in a research report on Monday, December 29th. BTIG Research restated a “buy” rating and set a $10.00 price objective on shares of Invivyd in a research report on Thursday, February 26th. Finally, D. Boral Capital restated a “hold” rating on shares of Invivyd in a research report on Tuesday, November 25th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Invivyd presently has an average rating of “Hold” and a consensus price target of $8.00.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.